Enclomiphene as an Emerging Therapeutic
The SERM That May Yet Get FDA Attention
Evidence grade 3 of 5, Mixed. Read how the Atlas grades evidence.
The written rationale for this grade is still being prepared.
- FDA
- Not FDA-approved (Androxal received Complete Response Letters); off-label via compounding
Reference only. Not medical advice.
What can go wrong
As a SERM, potential effects include mood changes, visual disturbances, and (class concern) venous thromboembolism risk seen with related agents. Long-term safety in this off-label use is not fully characterized. Because U.S. supply is compounded, purity and potency vary by pharmacy. Raising testosterone still requires monitoring (hematocrit, estradiol, PSA-area considerations).
This is something to take to a clinician. The Atlas can tell you what is known about enclomiphene as an emerging therapeutic in general. It cannot tell you what is happening in your body, and the difference matters most for exactly the symptoms that bring people to this page.
Enclomiphene is the trans-isomer of clomiphene citrate, a selective estrogen receptor modulator (SERM). By blocking estrogen's negative feedback at the hypothalamus and pituitary, it raises LH and FSH and stimulates a man's own testosterone production, without the testicular shutdown and fertility loss that exogenous testosterone causes. Developed as Androxal by Repros Therapeutics for secondary hypogonadism, it received Complete Response Letters from the FDA (notably 2015) and was never approved. Today it is used off-label, largely through compounding pharmacies and men's telehealth clinics.
A fertility-sparing way to raise a man's own testosterone, that never finished the FDA gauntlet.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
Enclomiphene antagonizes estrogen receptors at the hypothalamus and pituitary, removing estrogen's negative feedback. This increases GnRH-driven LH and FSH secretion, which stimulates Leydig cells to make testosterone and supports spermatogenesis. Because it works through the patient's own axis rather than supplying outside testosterone, it tends to preserve testicular size and fertility.
Why it stalled at the FDA
The FDA's Complete Response Letters faulted the Phase 3 program design, entry criteria, titration, and bioanalytical validation, and concluded the studies as built no longer adequately demonstrated clinical benefit, requesting additional Phase 3 work. Those studies were never completed, plausibly affected by corporate changes (Allergan's 2017 acquisition of Repros). So enclomiphene is not a failed-on-efficacy drug so much as an unfinished regulatory story.
Safety in detail
Enclomiphene is not FDA-approved and is used off-label, typically as a compounded product of variable purity. It manipulates the hormonal axis and requires physician evaluation and monitoring.
What it does to fertility
Generally preserves or supports fertility because it raises LH/FSH and intratesticular testosterone rather than suppressing the axis, a key reason it is chosen over exogenous testosterone by men who want to conceive.
What has to be monitored
The bloodwork this needs, and the reason it belongs with a clinician rather than a website.
- Total/free testosterone
- LH/FSH
- Estradiol
- Hematocrit
- Visual/mood symptoms
What people get wrong
Often saidEnclomiphene is FDA-approved for low T
ActuallyIt is not approved. It is used off-label, largely compounded, after Androxal received Complete Response Letters.
Often saidIt is just clomiphene
ActuallyIt is the trans-isomer of clomiphene, isolated to retain the testosterone-raising effect while reducing the estrogenic activity attributed to the other isomer.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
At a glance
- Class
- SERM (trans-isomer of clomiphene)
- Developer
- Repros Therapeutics (Androxal)
- FDA status
- Complete Response Letter(s); not approved
- Key advantage
- Raises endogenous testosterone while preserving fertility
- Current access
- Off-label, compounded
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Enclomiphene as an Emerging Therapeutic. A short entry is not a safe entry.
- Timeline. We have not built the dated record of research and regulatory events.
- Cost and market. We have not documented what it sells for or who sells it.
- Supply chain. We have not mapped where it is made.
- Who uses it. We have not documented the user groups.
- What could change. No forward-looking summary yet.
- How it compares. We have not set it against the alternatives.
- Children and teenagers. We have not checked what is known about younger people.
Sources
The studies below are named and described, but not linked. You cannot open them from here and check our reading against them, which means this page is our summary of the literature rather than a document you can verify. Weigh it accordingly until the links exist.
The studies that matter
Androxal Phase 3 program (Repros)2009-2015
Raised testosterone while better preserving sperm counts than topical testosterone; nevertheless received Complete Response Letters citing trial-design concerns
Enclomiphene vs clomiphene/topical T comparisonsvarious
Consistently shows endogenous testosterone elevation with preserved gonadotropins and fertility markers